scispace - formally typeset
S

Steve Morris

Researcher at University College London

Publications -  84
Citations -  3180

Steve Morris is an academic researcher from University College London. The author has contributed to research in topics: Randomized controlled trial & Psychological intervention. The author has an hindex of 23, co-authored 79 publications receiving 2422 citations. Previous affiliations of Steve Morris include University of Bristol.

Papers
More filters
Journal ArticleDOI

Imaging biomarker roadmap for cancer studies.

James P B O'Connor, +78 more
TL;DR: Experts assembled to review, debate and summarize the challenges of IB validation and qualification produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical validation, biological/clinical validation and assessment of cost-effectiveness.
Journal ArticleDOI

Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.

Derek J. Hausenloy, +581 more
- 19 Oct 2019 - 
TL;DR: Remote ischaemic conditioning does not improve clinical outcomes at 12 months in patients with STEMI undergoing PPCI, and the primary combined endpoint was cardiac death or hospitalisation for heart failure at 12 years in the intention-to-treat population.
Journal ArticleDOI

Ammonia excretion in aquatic and terrestrial crabs

TL;DR: Evidence is presented for a crustacean Rhesus-like protein that shows high homology to the human RhesUS-like ammonia transporter both in its amino acid sequence and in its predicted secondary structure.
Journal ArticleDOI

Lancet Commission: Stem cells and regenerative medicine

TL;DR: It is argued that a combination of poor quality science, unclear funding models, unrealistic hopes, and unscrupulous private clinics threatens regenerative medicine's social licence to operate and a solution is recommended that lies in a coordinated strategy with four pillars.
Journal ArticleDOI

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.

TL;DR: Not offering breast cancer screening to women at lower risk could improve the cost-effectiveness of the screening program, reduce overdiagnosis, and maintain the benefits of screening.